Cann Group (ASX:CAN) announced the launch of new medical cannabis items to be sold to approved Special Access Scheme (SAS) patients.
As quoted in the press release:
Cann has entered into a distribution agreement with Symbion Pty Ltd, which supplies healthcare services and products to more than 4000 retail pharmacies and 1300 hospitals throughout Australia.
Symbion will carry Cann’s full range of imported products, for supply to approved SAS patients in line with each state’s legislative requirements.
Cann CEO, Peter Crock, said the Company is now entering its commercialisation phase, having successfully established a reliable cultivation and production capability.
“We are now operating our existing Southern and Northern production facilities at full capacity, with in excess of 40 harvests now completed, and we are advancing our product manufacturing capabilities with IDT Australia.”